Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 2, 2014, Pages 455-461

  Else, Tobias ^a   Williams, Andrew R ^c   Sabolch, Aaron ^b   Jolly, Shruti ^b   Miller, Barbra S ^b   Hammer, Gary D ^a  

^a Division of Metabolism Endocrinology and Diabetes   (United States)

^b UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; HYDROCORTISONE; MINERALOCORTICOID; MITOTANE;

ABDOMINAL PAIN; ADRENAL CORTEX CARCINOMA; ADRENALECTOMY; ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DISTANT METASTASIS; FEMALE; FEVER; FLANK PAIN; HUMAN; HYDROCORTISONE BLOOD LEVEL; INCIDENTAL FINDING; LAPAROSCOPIC SURGERY; MAJOR CLINICAL STUDY; MALE; NIGHT SWEAT; OVERALL SURVIVAL; PRIORITY JOURNAL; RARE DISEASE; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SEX RATIO; SURVIVAL RATE; TUMOR VOLUME; WEIGHT REDUCTION;

ADOLESCENT; ADRENAL CORTEX NEOPLASMS; ADRENALECTOMY; ADRENOCORTICAL CARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOTANE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84896739925     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2856     Document Type: Article

References (28)

1. Brix D, Allolio B, Fenske W, et al. Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol. 2010;58:609-615.
2. Leboulleux S, Deandreis D, et al. Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis? Eur J Endocrinol. 2010;162:1147-1153.
3. Miller BS, Ammori JB, Gauger PG, Broome JT, Hammer GD, Doherty GM. Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma. World J Surg. 2010; 34:1380-1385.
4. Miller BS, Gauger PG, Hammer GD, Doherty GM. Resection of adrenocortical carcinoma is less complete and local recurrence occurs sooner and more often after laparoscopic adrenalectomy than after open adrenalectomy. Surgery. 2012;152:1150-1157.
5. Palazzo FF, Sebag F, Sierra M, Ippolito G, Souteyrand P, Henry JF. Long-Term outcome following laparoscopic adrenalectomy for large solid adrenal cortex tumors. World J Surg. 2006;30:893-898.
6. TerzoloM,Angeli A, FassnachtM,et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356:2372-2380.
7. Huang H, Fojo T. Adjuvant mitotane for adrenocortical cancer-A recurring controversy. J Clin Endocrinol Metab. 2008;93:3730-3732.
8. Terzolo M, Fassnacht M, Ciccone G, Allolio B, Berruti A. Adjuvant mitotane for adrenocortical cancer-working through uncertainty. J Clin Endocrinol Metab. 2009;94:1879-1880.
9. Fassnacht M, Hahner S, Polat B, et al. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab. 2006;91:4501-4504.
10. Sabolch A, Feng M, Griffith K, Hammer G, Doherty G, Ben-Josef E. Adjuvant and definitive radiotherapy for adrenocortical carcinoma. Int J Radiat Oncol Biol Phys. 2011;80(5):1477-1484.
11. Habra MA, Ejaz S, Feng L, et al. A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:192-197.
12. Cerquetti L, Sampaoli C, Amendola D, et al. Mitotane sensitizes adrenocortical cancer cells to ionizing radiations by involvement of the cyclin B1/CDK complex in G2 arrest and mismatch repair enzymes modulation. Int J Oncol. 2010;37:493-501.
13. Abiven G, Coste J, Groussin L, et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisolsecreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab. 2006;91:2650-2655.
14. Assie G, Antoni G, Tissier F, et al. Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab. 2007; 92:148-154.
15. Bilimoria KY, Shen WT, Elaraj D, et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer. 2008;113:3130-3136.
16. Weiss LM, Medeiros LJ, Vickery AL Jr. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol. 1989;13:202-206.
17. Hanauer DA. EMERSE: The Electronic Medical Record Search Engine. AMIA Annu Symp Proc. 2006:941.
18. Fassnacht M, Johanssen S, Quinkler M, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM classification. Cancer. 2009;115:243-250.
19. Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med. 1990;322:1195-1201.
20. Miller BS, Gauger PG, Hammer GD, Giordano TJ, Doherty GM. Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade. Langenbecks Arch Surg. 2010;395:955-961.
21. Volante M, Bollito E, Sperone P, et al. Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification. Histopathology. 2009;55:535-543.
22. Berruti A, Terzolo M, Sperone P, et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer. 2005;12:657-666.
23. Bertherat J, Coste J, Bertagna X. Adjuvant mitotane in adrenocortical carcinoma.NEngl J Med. 2007;357:1256-1257; author reply 1259.
24. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087-2106.
25. Raymond VM, Else T, Everett JN, Long JM, Gruber SB, Hammer GD. Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:E119-E125.
26. Else T. Overview of genetic syndromes associated with adrenocortical cancer. In: Hammer GD, Else T, eds. Adrenocortical Carcinoma. 1st ed. New York: Springer; 2010:153-172.
27. Herrmann LJ, Heinze B, Fassnacht M, et al. TP53 germline mutations in adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2012;97:E476-E485.
28. Gonzalez KD, Noltner KA, Buzin CH, et al. Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol. 2009;27:1250-1256.